Cancer Letters
Natural killer cell therapy: A new frontier for obesity-associated cancer
Publication date: 1 June 2022Source: Cancer Letters, Volume 535Author(s): Eimear Mylod, Joanne Lysaght, Melissa J. Conroy
Cancer Letters
Macrophage inhibitory cytokine-1 in cancer: Beyond the cellular phenotype
Publication date: Available online 26 March 2022Source: Cancer LettersAuthor(s): Sakthivel Muniyan, Ramesh Pothuraju, Parthasarathy Seshacharyulu, Surinder K. Batra
Cancer Letters
EWI2 promotes endolysosome-mediated turnover of growth factor receptors and integrins to suppress lung cancer
Publication date: Available online 24 March 2022Source: Cancer LettersAuthor(s): Jie Wang, Jonathan D. Wren, Yingjun Ding, Junxiong Chen, Nikhil Mittal, Chao Xu, Xing Li, Cengxi Zeng, Meng Wang, Jing Shi, Yanhui H. Zhang, Sangyoon J. Han, Xin A. Zhang
Cancer Letters
An aldehyde dehydrogenase 1A3 inhibitor attenuates the metastasis of human colorectal cancer
Publication date: Available online 22 March 2022Source: Cancer LettersAuthor(s): Jiang-Jie Duan, Di Wang, Jiao Cai, Jun-jie Chen, Xiao-Xia Zheng, Tian-qing Chen, Jun Wang, Xiao Zhang, Qing-Kai Yang, Shi-Cang Yu
Cancer Letters
Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma
Publication date: Available online 17 March 2022Source: Cancer LettersAuthor(s): Haiqin Wang, Xiaojuan Xiao, Zhenzhen Li, Saiqun Luo, Lei Hu, Hui Yi, Ruohong Xiang, Yu Zhu, Yanpeng Wang, Lin Zhu, Ling Xiao, Chongwen Dai, Abdul Aziz, Lingli Yuan, Yajuan…
Cancer Letters
Sperm associated antigen 4 promotes SREBP1-mediated <em>de novo</em> lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma
Publication date: Available online 17 March 2022Source: Cancer LettersAuthor(s): Tengfei Liu, Junming Yu, Chao Ge, Fangyu Zhao, Jing Chen, Chunxiao Miao, Wenjiao Jin, Qingqing Zhou, Qin Geng, Hechun Lin, Hua Tian, Taoyang Chen, Haiyang Xie, Ying Cui, M…
Cancer Letters
ETV4 potentiates nuclear YAP retention and activities to enhance the progression of hepatocellular carcinoma
Publication date: Available online 13 March 2022Source: Cancer LettersAuthor(s): Xiaoli Xu, Boshi Wang, Yun Liu, Tiantian Jing, Guiqin Xu, Li Zhang, Kun jiao, Zehong Chen, Lvzhu Xiang, Chen Xu, Zhaojuan Yang, Yongzhong Liu
Cancer Letters
The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux
Publication date: 1 June 2022Source: Cancer Letters, Volume 535Author(s): Bo Ni, Qing Li, Chun Zhuang, Peiqi Huang, Xiang Xia, Linxi Yang, Xinli Ma, Chen Huang, Wenyi Zhao, Lin Tu, Yanying Shen, Chunchao Zhu, Zizhen Zhang, Enhao Zhao, Ming Wang, Hui Cao
Cancer Letters
PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma
Publication date: 28 June 2022Source: Cancer Letters, Volume 536Author(s): Chenglong Chen, Yu Guo, Qingshan Huang, Boyang wang, Wei Wang, Jianfang Niu, Jingbing Lou, Jiuhui Xu, Tingting Ren, Yi Huang, Wei Guo